Asset Management One Co. Ltd. Sells 2,590 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Asset Management One Co. Ltd. lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 3.8% during the 4th quarter, Holdings Channel reports. The firm owned 65,363 shares of the biopharmaceutical company’s stock after selling 2,590 shares during the period. Asset Management One Co. Ltd.’s holdings in Alnylam Pharmaceuticals were worth $15,554,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ALNY. Huntington National Bank raised its stake in Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares during the period. Hollencrest Capital Management purchased a new position in Alnylam Pharmaceuticals during the 3rd quarter valued at approximately $29,000. R Squared Ltd purchased a new position in Alnylam Pharmaceuticals during the 4th quarter valued at approximately $33,000. Washington Trust Advisors Inc. purchased a new position in Alnylam Pharmaceuticals during the 3rd quarter valued at approximately $42,000. Finally, True Wealth Design LLC grew its holdings in Alnylam Pharmaceuticals by 15,300.0% during the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 153 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ALNY. Canaccord Genuity Group raised their price target on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a report on Friday, November 1st. Morgan Stanley raised their price target on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an “equal weight” rating in a report on Friday. Chardan Capital restated a “buy” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, January 13th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $299.43.

Alnylam Pharmaceuticals Trading Down 3.2 %

Shares of NASDAQ ALNY opened at $256.45 on Friday. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The business has a fifty day simple moving average of $254.03 and a two-hundred day simple moving average of $263.35. The firm has a market cap of $33.08 billion, a PE ratio of -97.88 and a beta of 0.35. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.24 earnings per share for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, EVP Tolga Tanguler sold 1,469 shares of the business’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $368,689.62. Following the completion of the transaction, the executive vice president now directly owns 13,191 shares of the company’s stock, valued at approximately $3,310,677.18. The trade was a 10.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Yvonne Greenstreet sold 5,219 shares of the business’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $1,309,864.62. Following the completion of the transaction, the chief executive officer now directly owns 78,880 shares of the company’s stock, valued at approximately $19,797,302.40. The trade was a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 73,964 shares of company stock valued at $20,622,925 in the last ninety days. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.